{"id":9469,"date":"2021-04-28T13:28:41","date_gmt":"2021-04-28T20:28:41","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9469"},"modified":"2021-04-29T13:29:31","modified_gmt":"2021-04-29T20:29:31","slug":"safety-and-immunogenicity-of-one-versus-two-doses-of-the-covid-19-vaccine-bnt162b2-for-patients-with-cancer-interim-analysis-of-a-prospective-observational-study","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/28\/safety-and-immunogenicity-of-one-versus-two-doses-of-the-covid-19-vaccine-bnt162b2-for-patients-with-cancer-interim-analysis-of-a-prospective-observational-study\/","title":{"rendered":"Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Among patients with cancer, one dose of the Pfizer-BioNTech vaccine did not elicit a strong antibody response. In a prospective observational study, the proportion of positive anti-S IgG titers measured at 21 days after vaccination was 38% among patients with solid cancers (21\/56 patients), 18% among patients with hematological cancer (8\/44), and 94% (32\/34) among individuals without cancer. Among participants who received a second dose 21 days later and for whom blood samples were available 2 weeks after the second dose, 95% (18\/19) of patients with solid cancer,<\/span><span style=\"font-weight: 400\"> 60% (3\/5) of patients with hematological cancers, and 100% of individuals without cancer were seropositive.\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Monin et al.\u00a0(Apr 27, 2021). Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study. The Lancet Oncology. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(21)00213-8\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/S1470-2045(21)00213-8<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Among patients with cancer, one dose of the Pfizer-BioNTech vaccine did not elicit a strong antibody response. In a prospective observational study, the proportion of positive anti-S IgG titers measured at 21 days after vaccination was 38% among patients with solid cancers (21\/56 patients), 18% among patients with hematological cancer (8\/44), and 94% (32\/34) among&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/28\/safety-and-immunogenicity-of-one-versus-two-doses-of-the-covid-19-vaccine-bnt162b2-for-patients-with-cancer-interim-analysis-of-a-prospective-observational-study\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[147],"topic":[31],"class_list":["post-9469","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccination","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9469"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9469\/revisions"}],"predecessor-version":[{"id":9470,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9469\/revisions\/9470"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9469"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}